US 12,138,488 B2
Methods of treating cancer with drugs
Vijay Agarwal, New York, NY (US); Braden Eliason, Minneapolis, MN (US); and Jeremy Ling, Mendota Heights, MN (US)
Assigned to Alpheus Medical, Inc., Chanhassen, MN (US)
Filed by Alpheus Medical, Inc., Chanhassen, MN (US)
Filed on Dec. 14, 2023, as Appl. No. 18/540,651.
Application 18/540,651 is a continuation of application No. 18/125,959, filed on Mar. 24, 2023, granted, now 11,865,372.
Application 18/125,959 is a continuation of application No. 17/733,868, filed on Apr. 29, 2022, granted, now 11,617,904, issued on Apr. 4, 2023.
Application 17/733,868 is a continuation of application No. 17/399,996, filed on Aug. 11, 2021, granted, now 11,318,332, issued on May 3, 2022.
Application 17/399,996 is a continuation of application No. PCT/US2020/017983, filed on Feb. 12, 2020.
Claims priority of provisional application 62/805,186, filed on Feb. 13, 2019.
Prior Publication US 2024/0108917 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 7/00 (2006.01); A61B 17/00 (2006.01); A61B 17/32 (2006.01); A61B 18/00 (2006.01); A61F 7/00 (2006.01); A61F 7/02 (2006.01); A61K 9/00 (2006.01); A61K 31/197 (2006.01); A61K 41/00 (2020.01); A61M 21/00 (2006.01); A61M 21/02 (2006.01); A61P 35/00 (2006.01); B06B 1/02 (2006.01); B06B 1/06 (2006.01)
CPC A61N 7/00 (2013.01) [A61F 7/0085 (2013.01); A61K 9/0053 (2013.01); A61K 31/197 (2013.01); A61K 41/0033 (2013.01); A61K 41/0061 (2013.01); A61M 21/02 (2013.01); A61P 35/00 (2018.01); B06B 1/0207 (2013.01); B06B 1/0622 (2013.01); A61B 2017/00084 (2013.01); A61B 2017/320069 (2017.08); A61B 2018/00023 (2013.01); A61B 2018/00446 (2013.01); A61F 2007/0056 (2013.01); A61F 2007/0096 (2013.01); A61F 2007/0288 (2013.01); A61M 2021/0027 (2013.01); A61M 2021/005 (2013.01); A61N 2007/003 (2013.01); A61N 2007/006 (2013.01); A61N 2007/0073 (2013.01); A61N 2007/0078 (2013.01); A61N 2007/0082 (2013.01); A61N 2007/0095 (2013.01); B06B 2201/76 (2013.01)] 20 Claims
 
1. A non-invasive method of treating cancer with a drug, comprising:
administering a drug to a patient with cancer cells,
wherein said drug results in increased production of a porphyrin compound,
wherein said porphyrin compound is accumulated in said cancer cells, activating said porphyrin compound via ultrasound,
wherein said ultrasound is defocused or planar,
wherein said activating said porphyrin compound results in said porphyrin compound causing apoptosis of said cancer cells; and
cooling said patient by circulating a cooling fluid.